075 – Cyclerion SCRAPS Sickle Cell Disease to Focus on CNS! Hepion Interview Follow Up

Cyclerion effectively fails in their Phase 2 Sickle Cell Disease trial but shows mixed CNS data. I go through the positive aspects of the data and discuss the potential for the company (and my position). In the latter part of the video, I do a follow up to the Hepion interview I did with the CEO, Dr. Robert Foster. I also talk about how I plan to play the stock given the upcoming catalysts.

I also touch on Amgen and their AMG510 Phase 2 data that was released in early Oct/2020.

If you want to help out the show (or join the discord), take a look at my patreon: https://www.patreon.com/breakingbiotech

Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com http://www.breakingbiotech.com #breakingbiotech

Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech


037 – Sangamo Bounces Back! Viking’s Backup Drug

In this video, I go through Sangamo’s updated data with their Hemophilia A and Beta-Thalassemia treatments. I also talk about Viking Therapeutics’ VK5211, a potent selective androgen receptor modulator.

Follow me @matthewlepoire

*This is not investment advice*


#breakingbiotech #SGMO #VKTX


034 – FDA’s Gottlieb Resigns plus AMRN Breakdown

In this episode, I talk about the latest news in the biotech sector with details on my DCF model for Amarin and their fish oil pill, vascepa. I also talk about the limb-girdle data from Sarepta.

Hit the like and subscribe button!

*this is not investment advice*



032 – GILD Fails Phase 3 in NASH!

On this episode, I talk about results from the Gilead Phase 3 NASH trial that announced no improvement in patients treated with Selonsertib (ASK1 inhibitor). I also talk about the DBVT BLA resubmission and a hot hot Q319 trading idea on CBIO.

Relevant links:

*this is not investment advice, only my opinion and ideas*


#biotech #breakingbiotech #nash


026 – Global Blood Therapeutics’ Meager Approval Attempt

Sickle cell disease (SCD) is a genetic condition whereby mutated hemoglobin has a tendency to form polymers after unloading oxygen. These polymers cause red blood cells to form a ‘sickle’ shape and increases their likelihood of sticking to the blood vessel wall, causing vaso-occlusive crises (VOCs), stroke, or other serious problems. VOCs are painful episodes due to ischemic obstruction of blood vessels that risk permanent organ damage. Trials for new medicines are required to measure VOCs by some metric (hospitalization time, opioid requirement, etc), to show that any improvement in hemoglobin actually leads to a better clinical outcome. Hydroxyurea is the current standard of care, and has been shown to increase hemoglobin and reduce VOCs. However, there is a major unmet medical need in this area, as hydroxyurea is limited in the magnitude of its effects and leaves patients with debilitating SCD symptoms.

Voxelotor is a once-daily, oral SCD treatment by Global Blood Therapeutics (GBT). Once in circulation, Voxelotor binds to hemoglobin and keeps it in a normal conformation, preventing red blood cell sickling. The company is in the middle of Phase 3 trials, recently releasing preliminary data from their HOPE trial. These data show a convincing effect on raising hemoglobin more than 1g/dl, enough to meet their primary endpoint. The company is so convinced of the results of Voxelotor that they recently asked the FDA for accelerated approval based on the clinically meaningful increase in hemoglobin and improvement in hemolysis.

Unfortunately for GBT, it was previously agreed upon that the company would also have to meet an objective related to VOCs before full approval. SCD symptom exacerbation was measured from patient-reported outcomes (PRO) using a hand-held instrument, which was designed by GBT to capture the full range of daily SCD symptoms. The latest data released from the HOPE study showed that Voxelotor led to numerically fewer VOC episodes but this difference was not statistically significant. The company had also planned on measuring hopitalizations and red blood cell transfusions, but this data has not yet been reported.

Given this, it seems unlikely that the FDA would accept accelerated approval of Voxelotor with the current results. GBT is set to release more data at the American Society of Hematology conference on December 3rd, 2018. Here, we may get more insight into the secondary endpoints, to see whether Voxelotor has an effect on VOCs. Without an effect on VOCs, I do not expect the company to get support from the FDA.

I do not have a position in the company, nor do I intend to initiate one. Follow me on twitter @matthewlepoire to see if that changes.

I get into more details and a portfolio update in my latest video:


Relevant Press Releases:
Relevant Links:


Gene therapy/CAR-T breakdown. Bluebird falls on GBT news

Gene therapy and car-t are leading the way in new potential treatments of blood disorders. I breakdown how these techniques work and which companies are using the technology.

Follow me @matthewlepoire


*This is not trading advice*

%d bloggers like this: